These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

133 related items for PubMed ID: 10470235

  • 1. Quantitative detection of tumor M2-PK in serum and plasma.
    Hugo F, Fischer G, Eigenbrodt E.
    Anticancer Res; 1999; 19(4A):2753-7. PubMed ID: 10470235
    [Abstract] [Full Text] [Related]

  • 2. Marker for renal cell carcinoma (RCC): the dimeric form of pyruvate kinase type M2 (Tu M2-PK).
    Wechsel HW, Petri E, Bichler KH, Feil G.
    Anticancer Res; 1999; 19(4A):2583-90. PubMed ID: 10470199
    [Abstract] [Full Text] [Related]

  • 3. The pyruvate kinase isoenzyme tumor M2 (Tu M2-PK) as a tumor marker for renal carcinoma.
    Oremek GM, Teigelkamp S, Kramer W, Eigenbrodt E, Usadel KH.
    Anticancer Res; 1999; 19(4A):2599-601. PubMed ID: 10470201
    [Abstract] [Full Text] [Related]

  • 4. Pre-analytical problems in the measurement of tumor type pyruvate kinase (tumor M2-PK).
    Oremek GM, Gerstmeier F, Sauer-Eppel H, Sapoutzis N, Wechsel HW.
    Anticancer Res; 2003; 23(2A):1127-30. PubMed ID: 12820359
    [Abstract] [Full Text] [Related]

  • 5. Tumor type M2-pyruvate-kinase levels in pleural fluid versus plasma in cancer patients: a further tool to define the need for invasive procedures.
    Elia S, Massoud R, Guggino G, Cristino B, Cortese C, De Massimi AR, Zenobi R.
    Eur J Cardiothorac Surg; 2008 Apr; 33(4):723-7. PubMed ID: 18261916
    [Abstract] [Full Text] [Related]

  • 6. Quantitative detection of tumor M2-pyruvate kinase in plasma of patients with lung cancer in comparison to other lung diseases.
    Schneider J, Morr H, Velcovsky HG, Weisse G, Eigenbrodt E.
    Cancer Detect Prev; 2000 Apr; 24(6):531-5. PubMed ID: 11198266
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Fuzzy logic-based tumor marker profiles including a new marker tumor M2-PK improved sensitivity to the detection of progression in lung cancer patients.
    Schneider J, Peltri G, Bitterlich N, Neu K, Velcovsky HG, Morr H, Katz N, Eigenbrodt E.
    Anticancer Res; 2003 Apr; 23(2A):899-906. PubMed ID: 12820320
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of the Pyruvate Kinase isoenzyme tumor (Tu M2-PK) as a tumor marker for cervical carcinoma.
    Kaura B, Bagga R, Patel FD.
    J Obstet Gynaecol Res; 2004 Jun; 30(3):193-6. PubMed ID: 15210041
    [Abstract] [Full Text] [Related]

  • 10. Quantification of tumor type M2 pyruvate kinase (Tu M2-PK) in human carcinomas.
    Eigenbrodt E, Basenau D, Holthusen S, Mazurek S, Fischer G.
    Anticancer Res; 1997 Jun; 17(4B):3153-6. PubMed ID: 9329624
    [Abstract] [Full Text] [Related]

  • 11. Tumor M2-pyruvate kinase: a promising tumor marker in the diagnosis of gastro-intestinal cancer.
    Hardt PD, Ngoumou BK, Rupp J, Schnell-Kretschmer H, Kloer HU.
    Anticancer Res; 2000 Jun; 20(6D):4965-8. PubMed ID: 11326648
    [Abstract] [Full Text] [Related]

  • 12. Tumor M2 pyruvate kinase: a tumor marker and its clinical application in gastrointestinal malignancy.
    Hardt PD, Ewald N.
    Expert Rev Mol Diagn; 2008 Sep; 8(5):579-85. PubMed ID: 18785806
    [Abstract] [Full Text] [Related]

  • 13. Pyruvate kinase isoenzyme M2 is not of diagnostic relevance as a marker for oral cancer.
    Ervens J, Fuchs H, Niemann VT, Hoffmeister B.
    J Craniomaxillofac Surg; 2008 Mar; 36(2):89-94. PubMed ID: 18243718
    [Abstract] [Full Text] [Related]

  • 14. Comparison of the tumor markers tumor M2-PK, CEA, CYFRA 21-1, NSE and SCC in the diagnosis of lung cancer.
    Schneider J, Velcovsky HG, Morr H, Katz N, Neu K, Eigenbrodt E.
    Anticancer Res; 2000 Mar; 20(6D):5053-8. PubMed ID: 11326667
    [Abstract] [Full Text] [Related]

  • 15. Tumour M2-pyruvate kinase: a gastrointestinal cancer marker.
    Kumar Y, Tapuria N, Kirmani N, Davidson BR.
    Eur J Gastroenterol Hepatol; 2007 Mar; 19(3):265-76. PubMed ID: 17301655
    [Abstract] [Full Text] [Related]

  • 16. Value of tumor M2-PK in thyroid carcinoma: a pilot study.
    Bena-Boupda NF, Rezai SS, Klett R, Eigenbrodt E, Bauer R.
    Anticancer Res; 2003 Mar; 23(6D):5237-40. PubMed ID: 14981996
    [Abstract] [Full Text] [Related]

  • 17. Plasma concentrations of tumour dimeric pyruvate kinase are increased in patients with chronic cardiac failure.
    McDowell G, Gupta S, Dellerba M, Coppinger T, Levy RD, Keevil BG.
    Ann Clin Biochem; 2004 Nov; 41(Pt 6):491-3. PubMed ID: 15588442
    [Abstract] [Full Text] [Related]

  • 18. Improved sensitivity in the diagnosis of gastro-intestinal tumors by fuzzy logic-based tumor marker profiles including the tumor M2-PK.
    Schneider J, Bitterlich N, Schulze G.
    Anticancer Res; 2005 Nov; 25(3A):1507-15. PubMed ID: 16033052
    [Abstract] [Full Text] [Related]

  • 19. Clinical significance of serum tumour M2-PK and CA19-9 detection in the diagnosis of cholangiocarcinoma.
    Li YG, Zhang N.
    Dig Liver Dis; 2009 Aug; 41(8):605-8. PubMed ID: 19168405
    [Abstract] [Full Text] [Related]

  • 20. Value of the serum levels of the tumor marker TUM2-PK in pancreatic cancer.
    Oremek GM, Eigenbrodt E, Rädle J, Zeuzem S, Seiffert UB.
    Anticancer Res; 1997 Aug; 17(4B):3031-3. PubMed ID: 9329593
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.